GlobeNewswire
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
➖
AI Sentiment
Neutral
5/10
- Home
- ABEO
as of 03-09-2026 12:07pm EST
$5.00
+$0.14
+2.99%
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 280.2M | IPO Year: | 2005 |
| Target Price: | $18.20 | AVG Volume (30 days): | 924.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.35 | EPS Growth: | 38.74 |
| 52 Week Low/High: | $3.93 - $7.54 | Next Earning Date: | N/A |
| Revenue: | $2,998,000 | Revenue Growth: | 258.18% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1589.77% |
| P/E Ratio: | 3.60 | Index: | N/A |
| Free Cash Flow: | -58461000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
Alvino Mark
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
2,000
Total Value
$10,181.20
Owned After
84,065
SEC Form 4
Crombez Eric
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
16,284
Total Value
$82,895.33
Owned After
63,456
SEC Form 4
Alland Leila
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
18,065
Total Value
$91,961.69
Owned After
173,614
SEC Form 4
Silverstein Christine Berni
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
20,070
Total Value
$102,168.34
Owned After
137,722
SEC Form 4
Wuchterl Donald A.
Sell
Director
ABEO Feb 2, 2026
Avg Cost/Share
$5.09
Shares
14,814
Total Value
$75,412.15
Owned After
167,935
SEC Form 4
O'Malley Brendan M.
Sell
SVP, Chief Legal Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.33
Shares
13,578
Total Value
$72,382.96
Owned After
451,134
SEC Form 4
Vazzano Joseph Walter
Sell
Chief Financial Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.33
Shares
18,666
Total Value
$99,506.58
Owned After
568,560
SEC Form 4
Seshadri Vishwas
Sell
Chief Executive Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.33
Shares
69,832
Total Value
$372,267.41
Owned After
1,460,408
SEC Form 4
Vasanthavada Madhav
Sell
Chief Commercial Officer
ABEO Jan 22, 2026
Avg Cost/Share
$5.29
Shares
12,610
Total Value
$66,657.72
Owned After
318,619
SEC Form 4
Alvino Mark
Sell
Director
ABEO Jan 21, 2026
Avg Cost/Share
$5.23
Shares
13,500
Total Value
$70,573.95
Owned After
84,065
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Alvino Mark | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 2,000 | $10,181.20 | 84,065 | |
| Crombez Eric | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 16,284 | $82,895.33 | 63,456 | |
| Alland Leila | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 18,065 | $91,961.69 | 173,614 | |
| Silverstein Christine Berni | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 20,070 | $102,168.34 | 137,722 | |
| Wuchterl Donald A. | ABEO | Director | Feb 2, 2026 | Sell | $5.09 | 14,814 | $75,412.15 | 167,935 | |
| O'Malley Brendan M. | ABEO | SVP, Chief Legal Officer | Jan 22, 2026 | Sell | $5.33 | 13,578 | $72,382.96 | 451,134 | |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Jan 22, 2026 | Sell | $5.33 | 18,666 | $99,506.58 | 568,560 | |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Jan 22, 2026 | Sell | $5.33 | 69,832 | $372,267.41 | 1,460,408 | |
| Vasanthavada Madhav | ABEO | Chief Commercial Officer | Jan 22, 2026 | Sell | $5.29 | 12,610 | $66,657.72 | 318,619 | |
| Alvino Mark | ABEO | Director | Jan 21, 2026 | Sell | $5.23 | 13,500 | $70,573.95 | 84,065 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 12, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 12, 2025 · 100% conf.
AI Prediction SELL
1D
-2.22%
$4.84
5D
-5.29%
$4.69
20D
-8.67%
$4.52
Price: $4.95 Prob +5D: 0% AUC: 1.000
0001493152-25-021721
false 0000318306
0000318306
2025-11-12 2025-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 12, 2025
ABEONA
THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
001-15771
83-0221517
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
6555 Carnegie Ave, 4th Floor
Cleveland,
OH 44103
(Address of principal executive offices) (Zip Code)
(646) 813-4701
(Registrant’s telephone number, including area code)
N /A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 par value
ABEO
The Nasdaq Capital Market
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 12, 2025, Abeona Therapeutics Inc. issued a press release regarding its financial results for the quarter ended September 30, 2025. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated November 12, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Abeona Therapeutics Inc.
(Registrant)
By: /s/ Joseph Vazzano
Name: Joseph Vazzano
Title: Chief Financial Officer
Date: November 12, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 14, 2025
0001641172-25-023715
false 0000318306
0000318306
2025-08-14 2025-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 14, 2025
ABEONA
THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
001-15771
83-0221517
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S.
Employer
Identification No.)
6555 Carnegie Ave, 4th Floor
Cleveland,
OH 44103
(Address of principal executive offices) (Zip Code)
(646) 813-4701
(Registrant’s telephone number, including area code)
N /A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 par value
ABEO
The Nasdaq Capital Market
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2025, Abeona Therapeutics Inc. issued a press release regarding its financial results for the quarter ended June 30, 2025. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated August 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Abeona Therapeutics Inc.
(Registrant)
By: /s/ Joseph Vazzano
Name: Joseph Vazzano
Title: Chief Financial Officer
Date: August 14, 2025
2025 Q2 Q2 2025 Earnings
8-K Jul 2, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 2, 2025
0001641172-25-017460
false 0000318306
0000318306
2025-06-27 2025-06-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 27, 2025
ABEONA
THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
001-15771
83-0221517
(State or other jurisdiction
(Commission
(I.R.S.
Employer
of incorporation)
File Number)
Identification No.)
6555 Carnegie Ave, 4th Floor
Cleveland,
OH 44103
(Address of principal executive offices) (Zip Code)
(646) 813-4701
(Registrant’s telephone number, including area code)
N /A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 par value
ABEO
The Nasdaq Capital Market
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.01 Completion of Acquisition or Disposition of Assets.
On June 27, 2025, Abeona Therapeutics Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The Company was awarded the voucher on April 28, 2025, under a U.S. Food and Drug Administration (“FDA”) program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV upon approval of the Company’s biologics license application for ZEVASKYN™ (prademagene zamikeracel).
The Asset Sale was completed pursuant to the terms of an asset purchase agreement dated May 9, 2025 (the “PRV Asset Purchase Agreement”). Pursuant to the PRV Asset Purchase Agreement, the Company received gross proceeds of $155 million from the buyer upon the closing of the Asset Sale.
The foregoing description of the PRV Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by the full text of the PRV Asset Purchase Agreement, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2025.
Item 2.02 Results of Operations and Financial Condition.
On July 2, 2025, the Company issued a press release in relation to the Asset Sale, in which the Company announced that as of June 30, 2025, including the net proceeds from the Asset Sale, the Company’s unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information contained in this item, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
As noted above, on July 2, 2025, the Company announced that as of June 30, 2025, including the net proceeds from the Asset Sale, the Company’s unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million.
The foregoing unaudited cash, cash equivalents, restricted cash and short-term investments information provided in this Current Report on Form 8-K is based on preliminary unaudited information and management estimates for the quarter ended June 30, 2025, is not a comprehensive statement of the Company’s financial results as of and for the fiscal quarter ended June 30, 2025 or any other period, and is subject to completion of the Company’s financial closing proced
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
Compare ABEO vs Leading Stocks
See how ABEO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.